Clinical studies in other tumor entities, such as metastatic colorectal and non-small cell lung cancer, have shown that the use of anti-EGFR antibodies or tyrosine kinase inhibitors improves progression free and overall survival, but only for patients lacking a KRAS mutation. Here, KRAS is linked to non-small cell lung carcinoma.